Compare · LQDA vs TVTX
LQDA vs TVTX
Side-by-side comparison of Liquidia Corporation (LQDA) and Travere Therapeutics Inc. (TVTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LQDA and TVTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LQDA is the larger of the two at $5.80B, about 1.3x TVTX ($4.35B).
- Over the past year, LQDA is up 398.4% and TVTX is up 230.6% - LQDA leads by 167.8 points.
- LQDA has been more active in the news (23 items in the past 4 weeks vs 15 for TVTX).
- TVTX has more recent analyst coverage (25 ratings vs 16 for LQDA).
- Company
- Liquidia Corporation
- Travere Therapeutics Inc.
- Price
- $70.28+7.77%
- $47.98+2.65%
- Market cap
- $5.80B
- $4.35B
- 1M return
- +24.18%
- +12.08%
- 1Y return
- +398.40%
- +230.58%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 23
- 15
- Recent ratings
- 16
- 25
Liquidia Corporation
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension; and LIQ865, a sustained-release formulation of bupivacaine for the treatment of local post-operative pain. The company also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Travere Therapeutics Inc.
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences, and Alagille Syndrome Alliance for identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Latest LQDA
- Liquidia Announces Poster Presentations at the PHA 2026 International PH Conference and Scientific Sessions
- SEC Form 144 filed by Liquidia Corporation
- Chief Development Officer Khindri Sanjeev sold $270,612 worth of shares (4,134 units at $65.46) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 67,132 units (SEC Form 4)
- Director Bloch Stephen M sold $14,273,683 worth of shares (220,835 units at $64.64) (SEC Form 4)
- Director Manning Paul B sold $12,782,059 worth of shares (200,000 units at $63.91) (SEC Form 4)
- Director Bloch Stephen M sold $5,507,782 worth of shares (84,800 units at $64.95) (SEC Form 4)
- Liquidia Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 144 filed by Liquidia Corporation
- Liquidia Corporation Announces Inclusion in the S&P SmallCap 600® Index
- Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
Latest TVTX
- Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
- SEC Form 8-K filed by Travere Therapeutics Inc.
- Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
- Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy
- Director Williams Brinkley Ruth was granted 4,000 shares, increasing direct ownership by 16% to 29,750 units (SEC Form 4)
- Director Meckler Jeffrey A was granted 4,000 shares, increasing direct ownership by 5% to 91,500 units (SEC Form 4)
- Director Orwin John A was granted 4,000 shares, increasing direct ownership by 11% to 39,375 units (SEC Form 4)
- Director Poole Sandra was granted 4,000 shares, increasing direct ownership by 13% to 34,000 units (SEC Form 4)
- Director Squarer Ron was granted 4,000 shares, increasing direct ownership by 11% to 39,375 units (SEC Form 4)
- Director Baynes Roy D. was granted 4,000 shares, increasing direct ownership by 11% to 41,500 units (SEC Form 4)